Research map: A modular γδ TCR-T platform combining KRAS pMHC targeting with re-dosable mRNA engager redirection
Back to the article
Papers in this map
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
· Sattva Swarup Neelapu · 2017 · 6103 citations · Cited by this paper
Current and future immunotherapies for NSCLC
· 2026 · Related
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
· Shannon L. Maude · 2018 · 5822 citations · Cited by this paper
Antibody-oligonucleotide conjugates: design principles, intracellular delivery, and translational opportunities
· 2026 · Related
The prognostic landscape of genes and infiltrating immune cells across human cancers
· Andrew J. Gentles · 2015 · 3335 citations · Cited by this paper
Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting
· 2026 · Related
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
· Jesse Meir Zaretsky · 2016 · 3296 citations · Cited by this paper
BTKi orelabrutinib improved the outcome of newly-diagnosed PCNS-LBCL by alleviating MyD88L265P-induced PIM1 stability
· 2026 · Related
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
· Richard A. Morgan · 2010 · 2585 citations · Cited by this paper
Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working party
· 2026 · Related
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
· Donald M. O’Rourke · 2017 · 1838 citations · Cited by this paper
Cytokines and cancer-associated fibroblasts
· 2026 · Related
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
· Paul F. Robbins · 2011 · 1640 citations · Cited by this paper
Updated data of CLL1 CAR-T cell therapy in adult patients with relapsed/refractory acute myeloid leukemia
· 2025 · Related
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
· Laura A. Johnson · 2009 · 1426 citations · Cited by this paper
Immuno-cytotoxic convergence: integrating antibody‒drug conjugates and immunofusion proteins to overcome resistance in gastrointestinal cancers
· 2026 · Related
Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
· Pablo Tebas · 2014 · 1366 citations · Cited by this paper
Large language model-guided CAR-T in silico platform for cytokine optimization in liver cancer with low antigen density
· 2026 · Related
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
· Akin Akinc · 2010 · 1267 citations · Cited by this paper
CXCR4-antagonistic peptide-decorated lipid nanoparticles for co- delivery of AML1-ETO siRNA to enhance chemotherapy in refractory AML
· 2026 · Related
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
· Gerald P. Linette · 2013 · 1202 citations · Cited by this paper
The Frequency of Ras Mutations in Cancer
· Ian Andrew Prior · 2020 · 1164 citations · Cited by this paper
Reprogramming human T cell function and specificity with non-viral genome targeting
· Theodore L. Roth · 2018 · 887 citations · Cited by this paper
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
· Gregory Lawrence Beatty · 2013 · 875 citations · Cited by this paper
Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication
· Christopher C. Kloss · 2018 · 646 citations · Cited by this paper
Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells
· Marc Rigau · 2020 · 456 citations · Cited by this paper
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy
· Gavin M. Bendle · 2010 · 450 citations · Cited by this paper
Apolipoprotein E Binding Drives Structural and Compositional Rearrangement of mRNA-Containing Lipid Nanoparticles
· Federica Sebastiani · 2021 · 411 citations · Cited by this paper
Non-viral precision T cell receptor replacement for personalized cell therapy
· Susan P. Foy · 2022 · 294 citations · Cited by this paper
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies
· Christiane Stadler · 2017 · 290 citations · Cited by this paper
Engineering Artificial Antigen-presenting Cells to Express a Diverse Array of Co-stimulatory Molecules
· Megan M. Suhoski · 2007 · 270 citations · Cited by this paper
Butyrophilin-2A1 Directly Binds Germline-Encoded Regions of the Vγ9Vδ2 TCR and Is Essential for Phosphoantigen Sensing
· Mohindar Murugesh Karunakaran · 2020 · 270 citations · Cited by this paper
Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer
· Yan Xu · 2020 · 266 citations · Cited by this paper
Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template
· Blythe Duke Sather · 2015 · 231 citations · Cited by this paper
LAG3’s Enigmatic Mechanism of Action
· Colin G. Graydon · 2021 · 187 citations · Cited by this paper
Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function
· Kilian Schober · 2019 · 181 citations · Cited by this paper
Phosphoantigens glue butyrophilin 3A1 and 2A1 to activate Vγ9Vδ2 T cells
· Linjie Yuan · 2023 · 144 citations · Cited by this paper
Activating and Propagating Polyclonal Gamma Delta T Cells with Broad Specificity for Malignancies
· Drew C. Deniger · 2014 · 133 citations · Cited by this paper
Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6
· Rasmus Otkjær Bak · 2017 · 129 citations · Cited by this paper
Source: OpenAlex (CC0)